<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIM: Diabetic <z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">dyslipidaemia</z:e>, characterized by hypertriglyceridaemia as a result of elevated serum <z:chebi fb="0" ids="39027">very-low-density lipoprotein</z:chebi> (<z:chebi fb="1" ids="39027">VLDL</z:chebi>) concentrations, contributes to the increased risk of <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e>) in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> (T2DM) </plain></SENT>
<SENT sid="1" pm="."><plain>Proprotein convertase subtilisin/kexin type 9 (PCSK9) may play a role in regulating <z:chebi fb="1" ids="39027">VLDL</z:chebi> metabolism </plain></SENT>
<SENT sid="2" pm="."><plain>We investigated the effect of <z:chebi fb="0" ids="5001">fenofibrate</z:chebi> on serum PCSK9 and <z:chebi fb="1" ids="39027">VLDL</z:chebi> particle concentrations in T2DM patients already receiving <z:chebi fb="0" ids="35664">statin</z:chebi> therapy </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: In a double-blind randomized crossover study, 15 statin-treated T2DM patients (63 +/- 8 years, body mass index (BMI) 29 +/- 3 kg/m(2)) were treated with <z:chebi fb="0" ids="5001">fenofibrate</z:chebi> (145 mg/day) or matching placebo for 12 weeks </plain></SENT>
<SENT sid="4" pm="."><plain>Serum PCSK9 concentrations were measured by immunoassay </plain></SENT>
<SENT sid="5" pm="."><plain><z:chebi fb="1" ids="39027">VLDL</z:chebi> particle concentration and size were determined by nuclear magnetic resonance spectroscopy </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: <z:chebi fb="0" ids="5001">Fenofibrate</z:chebi> decreased serum <z:chebi fb="4" ids="17855">triglycerides</z:chebi> (-23%), <z:chebi fb="0" ids="47776">VLDL-triglycerides</z:chebi> (-51%), total cholesterol (-11%), <z:chebi fb="1" ids="47774">LDL-cholesterol</z:chebi> (-16%), <z:chebi fb="0" ids="39015">apolipoprotein</z:chebi> B-100 (-16%), <z:chebi fb="0" ids="39015">apolipoprotein</z:chebi> C-III (-20%) and PCSK9 (-13%) concentrations compared with placebo (p &lt; 0.05) </plain></SENT>
<SENT sid="7" pm="."><plain><z:chebi fb="0" ids="5001">Fenofibrate</z:chebi> also decreased serum concentrations of large (-45%), medium (-66%) and small <z:chebi fb="1" ids="39027">VLDL</z:chebi> (-67%) particles (p &lt; 0.05), without altering <z:chebi fb="1" ids="39027">VLDL</z:chebi> particle size </plain></SENT>
<SENT sid="8" pm="."><plain>Serum PCSK9 reduction correlated with decreases in total (r = 0.526, p = 0.044) and small (r = 0.629, p = 0.021) <z:chebi fb="1" ids="39027">VLDL</z:chebi> particle concentrations </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: <z:chebi fb="0" ids="5001">Fenofibrate</z:chebi> concomitantly decreased serum PCSK9 and <z:chebi fb="1" ids="39027">VLDL</z:chebi> particle concentrations in <z:chebi fb="0" ids="35664">statin</z:chebi>-treated T2DM patients </plain></SENT>
<SENT sid="10" pm="."><plain>These findings support a mechanistic link between PCSK9 and <z:chebi fb="1" ids="39027">VLDL</z:chebi> metabolism, possibly through an effect of PSK9 on <z:chebi fb="1" ids="39027">VLDL</z:chebi> receptor degradation </plain></SENT>
</text></document>